Klein Given New, Six-Month Term as Chairman; Board to Examine Criteria for Replacement
Directors of the California stem cell agency today re-elected Robert Klein as chairman of the $3 billion enterprise, culminating a weeks-long flap that included closed-door dealings, allegations of “sleazy” conduct and dubious, last minute financial warnings about CIRM's financial condition.
Klein said he would serve for no more than six months and woul…
Keep reading with a 7-day free trial
Subscribe to The California Stem Cell Report to keep reading this post and get 7 days of free access to the full post archives.